Targeting the Clinical Course of Hypertrophic Cardiomyopathy: Keeping a Beat on New and Emerging Therapies

Targeting the Clinical Course of Hypertrophic Cardiomyopathy: Keeping a Beat on New and Emerging Therapies is organized by Pharmacy Times Continuing Education (PTCE),Release date: October 1, 2022,Expiration date: October 1, 2023,Description:,Hypertrophic cardiomyopathy (HCM) is a condition wherein the muscles of the heart thicken or enlarge with left ventricular hypertrophy, which may be due to sarcomere gene variation. HCM is quite common, seen in 1 in every 500 people worldwide and in 600,000 individuals in the United States alone. Symptomatic treatment has been the mainstay of managing HCM, but recently 1 approved medication has been shown to treat the underlying cause of HCM, with several additional therapies under investigation. Such medication leads to improved quality of life and reduced overall costs for patients. Pharmacists play a key role in managing medications, screening for drug interactions and possible adverse reactions, and making recommendations for optimal treatment. Pharmacists should be informed and aware of newly available methods for the management of HCM, as they can be influential in providing the best possible care for their patients. This activity will equip pharmacists with knowledge of the disease characteristics of HCM, new and emerging medications, and opportunities to achieve optimal patient care.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Explain the underlying pathophysiologic mechanisms and presentation of hypertrophic cardiomyopathy (HCM) along with comorbidities that may place patients at risk for disease progression,• Analyze the mechanism of action and clinical data for recently approved and emerging therapies for HCM as well as patient populations eligible for treatment with novel agents,• Identify opportunities for pharmacists within health systems to facilitate access to medications and support patients with HCM in the initiation of therapy, monitoring of adverse effects, and adherence management